Multifunctional high boron content MOFs nano-co-crystals were assembled and architected for precise boron neutron capture therapy (BNCT) of brain glioma. Zirconium and mesotetra(4-carboxyphenyl)porphyrin are screened and determined to structure stable (Zr-TCPP) MOFs. The MOFs binding boron acids formed 100.20 ± 6.72 nm co-crystal structures (MNCs), which contained 42.50 % boric acid (m/m), had excellent stability, superior colloid dispersion, and excellent biocompatibility. Importantly, they could cross the brain-blood barrier, selectively target brain tumors, and deliver a high boron dose of 67.50 ± 4.20 µg [¹⁰B] g⁻¹. Inductively coupled plasma mass spectrometry showed an excellent tumor-to-normal tissue boron ratio of 6.20 ± 0.90 and tumor-to-blood boron ratio of 3.80 ± 0.35. The MNCs also had intrinsic fluorescence and Zr⁸⁹ positron emission tomography imaging capabilities, which can accurately trace and quantify MNCs in vitro and in vivo. Therefore, a significantly antitumor efficiency was achieved in BNCT for glioma in model mice by imaging location of precise space-time.

多功能高硼含量 MOFs 纳米共晶体被组装和构建用于脑胶质瘤的精确硼中子捕获治疗 (BNCT)。锆和中四（4-羧基苯基）卟啉被筛选并确定为结构稳定的（Zr-TCPP）MOF。MOFs 结合硼酸形成 100.20 ± 6.72 nm 的共晶结构 (MNCs)，其中含有 42.50% 硼酸 (m/m)，具有优异的稳定性、优异的胶体分散性和优异的生物相容性。重要的是，它们可以穿过脑血屏障，选择性地靶向脑肿瘤，并提供 67.50 ± 4.20 µg [ ¹⁰ B] g ^{-1的高硼剂量}. 电感耦合等离子体质谱显示肿瘤与正常组织的硼比率为 6.20 ± 0.90，肿瘤与血液的硼比率为 3.80 ± 0.35。跨国公司还具有固有荧光和Zr ⁸⁹正电子发射断层扫描成像能力，可以在体外和体内准确地追踪和量化跨国公司。因此，通过精确时空成像定位，BNCT对模型小鼠神经胶质瘤的抗肿瘤效果显着。